【.】評論

由flow chart 會偏向bone marrow hypoplasia, 接下來則會以IPSS-R計算為超過分6,為high risk; No particular cytoreductive bridging therapy has been shown to achieve superior outcomes following transplantation. However, a retrospective study of bridging therapy reported that, compared with intensive chemotherapy, treatment with azacitidine achieved a comparable rate of post-transplant relapse, but caused less toxicity [21]. In another study, outcomes were comparable whether pretransplant bridging therapy was azacitidine alone, intensive remission induction therapy alone, or azacitidine followed by intensive remission induction therapy [22]. Other studies reported that survival after allogeneic HCT was comparable whether patients proceeded directly to transplantation or received intensive remission induction therapy prior to allogeneic HCT ;依上文雖azacitidine較易有移植後復發,但依病人年紀大,仍考慮使用毒性較弱的azacitidine